Background: Activation of intravesical protease activated receptor 4 (PAR4) leads to release of urothelial macrophage migration inhibitory factor (MIF). MIF then binds to urothelial MIF receptors to release urothelial high mobility group box-1 (HMGB1) and elicit bladder hyperalgesia. Since MIF binds to multiple receptors, we investigated the contribution of individual urothelial MIF receptors to PAR4-induced HMGB1 release in vivo and in vitro and bladder pain in vivo.
Methodology/principal Findings: We tested the effect of intravesical pre-treatment with individual MIF or MIF receptor (CD74, CXCR4, CXCR2) antagonists on PAR4-induced HMGB1 release in vivo (female C57/BL6 mice) and in vitro (primary human urothelial cells) and on PAR4-induced bladder hyperalgesia in vivo (mice). In mice, PAR4 induced HMGB1 release and bladder hyperalgesia through activation of intravesical MIF receptors, CD74 and CXCR4. CXCR2 was not involved in these effects. In primary urothelial cells, PAR4-induced HMGB1 release through activation of CD74 receptors. Micturition parameters in mice were not changed by any of the treatments.
Conclusions/significance: Urothelial MIF receptors CD74 and CXCR4 mediate bladder pain through release of urothelial HMGB1. This mechanism may set up persistent pain loops in the bladder and warrants further investigation. Urothelial CD74 and CXCR4 may provide novel targets for interrupting bladder pain.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382170 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255975 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Integrative multi-omics analysis reveals a novel subtype of hepatocellular carcinoma with biological and clinical relevance.
Front Immunol
December 2024
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, ;China.
Background: Hepatocellular carcinoma (HCC) is a highly heterogeneous tumor, and the development of accurate predictive models for prognosis and drug sensitivity remains challenging.
Methods: We integrated laboratory data and public cohorts to conduct a multi-omics analysis of HCC, which included bulk RNA sequencing, proteomic analysis, single-cell RNA sequencing (scRNA-seq), spatial transcriptomics sequencing (ST-seq), and genome sequencing. We constructed a tumor purity (TP) and tumor microenvironment (TME) prognostic risk model.
A new perspective on macrophage-targeted drug research: the potential of in bladder cancer immunotherapy.
Front Immunol
December 2024
Department of Andrology, The First Hospital of Jilin University, Changchun, Jilin, China.
Introduction: Bladder cancer was recognized as one of the most common malignant tumors in the urinary system, and treatment options remained largely limited to conventional surgery, radiotherapy, and chemotherapy, which limited patient benefits.
Methods: Researchers constructed an RNA transcriptome map of bladder cancer by integrating single-cell RNA sequencing and clinical data, identifying potential molecular targets for diagnosis and treatment. We also verified the antitumor activity of the target through in vitro experiment.
Single-cell RNA sequencing analysis reveals potential key prognostic markers in hepatocellular carcinoma.
Discov Oncol
December 2024
Department of Oncology, The 940Th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, 333 Nan Bin He Road, Qilihe District, Lanzhou, 730050, Gansu, China.
Background: Hepatocellular carcinoma (HCC) is the sixth most frequently diagnosed cancer worldwide accompanied by a low 5-year survival rate. In our study, we aimed to analyze relevant genetic features that can predict the prognosis of HCC patients by single-cell RNA sequencing (scRNA-seq).
Methods: Single-cell RNA-seq data of HCC were analyzed from the Gene Expression Omnibus (GEO) database.
The VEGF-Mediated Cytoprotective Ability of MIF-Licensed Mesenchymal Stromal Cells in House Dust Mite-Induced Epithelial Damage.
Eur J Immunol
November 2024
Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Co. Kildare, Ireland.
Enhancing mesenchymal stromal cell (MSC) therapeutic efficacy through licensing with proinflammatory cytokines is now well established. We have previously shown that macrophage migration inhibitory factor (MIF)-licensed MSCs exerted significantly enhanced therapeutic efficacy in reducing inflammation in house dust mite (HDM)-driven allergic asthma. Soluble mediators released into the MSC secretome boast cytoprotective properties equal to those associated with the cell itself.
View Article and Find Full Text PDFImpact of Hashimoto's thyroiditis on the tumor microenvironment in papillary thyroid cancer: insights from single-cell analysis.
Front Endocrinol (Lausanne)
October 2024
Department of Pharmacogenomics, College of Bioinformatics and Science Technology, Harbin Medical University, Harbin, China.
Article Synopsis
- This study analyzes the effects of Hashimoto's thyroiditis (HT) on the microenvironment of papillary thyroid cancer (PTC) using extensive single-cell data from 11 patients.
- It highlights specific cell populations related to HT that create a thyroid-stimulating hormone (TSH)-suppressive environment and promote immune interactions, crucial for personalized medicine approaches.
- The research also introduces a new method for analyzing RNA-seq data, enhancing the understanding of the relationship between autoimmunity and cancer, and potentially revealing new therapeutic targets for PTC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!